文献速递其他结缔组织病

安罗替尼通过抑制NETs-PI3K/Akt驱动的上皮-间质转化改善肌炎相关间质性肺病

Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition.
PubMed 文献 · RMD Open · 2026-02-15

本研究在MAILD小鼠模型和NET诱导的人肺泡上皮细胞模型中探索安罗替尼的作用及机制。结果显示安罗替尼显著减轻肺纤维化和炎症,抑制NETs形成、PI3K/Akt激活及上皮-间质转化,并促进肺泡上皮修复与迁移。结论提示安罗替尼可能通过NETs-PI3K/Akt轴缓解MAILD进展。

要点

  • 安罗替尼减轻MAILD小鼠肺纤维化和炎症因子(TNF-α、IL-6、IL-1β)。
  • 安罗替尼抑制NETs形成、PI3K/Akt激活和上皮-间质转化。
  • 安罗替尼促进肺泡上皮细胞修复和迁移,支持药物重定位。

核心结论

  • 安罗替尼通过抑制NETs-PI3K/Akt轴及后续上皮-间质转化缓解MAILD进展。

研究设计与样本

  • 建立MAILD小鼠模型和NET诱导的人肺泡上皮细胞(A549)模型评估安罗替尼疗效。
  • 采用H&E和Masson染色分析肺病理和胶原沉积,免疫组化、免疫荧光和Western blot检测NETs、PI3K/Akt及EMT标志物。
  • RNA测序和基因集富集分析鉴定差异基因和信号通路,CCK-8、EdU和划痕实验评估细胞修复和迁移。

主要发现

  • MAILD小鼠肺显示结构损伤、炎症浸润、胶原沉积、NETs形成增加、PI3K/Akt激活和EMT增强。
  • 安罗替尼显著改善肺纤维化并降低促炎细胞因子TNF-α、IL-6、IL-1β。
  • 体内和体外实验中,安罗替尼抑制NETs形成、PI3K/Akt激活和EMT,同时增强肺泡上皮细胞修复和迁移。

临床怎么用

  • 安罗替尼可能作为MAILD的候选治疗药物,其机制涉及抑制NETs-PI3K/Akt轴和EMT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myositis-associated interstitial lung disease (MAILD) is one of the most severe complications of idiopathic inflammatory myopathy, characterised by rapidly progressive pulmonary fibrosis and high mortality. Treatment options are limited, and mechanisms driving epithelial-mesenchymal transition (EMT) in MAILD are incompletely understood. Anlotinib, a multitarget tyrosine kinase inhibitor, shows potential in fibrotic diseases; however, its role and mechanism in MAILD need clarification. METHODS: To assess anlotinib's therapeutic effects, we established a MAILD mouse model and a neutrophil extracellular trap (NET)-induced human alveolar epithelial cell (A549) model. H&E and Masson staining analysed lung pathological changes and collagen deposition. Immunohistochemistry, immunofluorescence and Western blot detected expressions of NETs markers (myeloperoxidase, citrullinated histone H3), phosphatidylinositol 3-kinase/protein kinase B (PI3K)/Akt components and EMT markers (E-cadherin, α-smooth muscle actin). RNA sequencing and gene set enrichment analysis identified differentially expressed genes and signalling pathways. Cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU) and wound healing assays assessed cellular repair and migration. RESULTS: MAILD mouse lungs showed structural damage, inflammatory infiltration, collagen deposition, increased NETs formation, PI3K/Akt activation and enhanced EMT. Anlotinib significantly ameliorated pulmonary fibrosis and reduced pro-inflammatory cytokines (tumour necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1β). In vivo and in vitro, anlotinib suppressed NETs formation, PI3K/Akt activation and EMT, while enhancing alveolar epithelial cell repair and migration. CONCLUSION: Anlotinib alleviates MAILD progression by inhibiting the NETs-PI3K/Akt axis and subsequent EMT, providing a theoretical basis for drug repurposing and supporting its clinical translation potential in MAILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Yang J, Chai H, Zhu J, et al. Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition. RMD Open. 2026. PMID: 41692509. doi:10.1136/rmdopen-2025-006443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。